[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-pulmonary-nodules\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-pulmonary-nodules":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,55,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642338","peripheral-blood-cytof-and-viral-imprinting-in-postoperative-multiple-pulmonary-nodules-100642338",false,"NCT07647484","Peripheral Blood CyTOF and Viral Imprinting in Postoperative Multiple Pulmonary Nodules","A Multicenter Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\nAge 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\nInvestigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","200 Months","OBSERVATIONAL","This multicenter prospective cohort study will enroll adults who have undergone resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up. During clinically indicated follow-up visits, a small amount of peripheral venous blood will be collected at the same time as routine blood draws for research CyTOF immune phenotyping and viral imprinting-related serology. The study will not assign participants to treatment, change follow-up schedules, imaging, medication, surgery, or other clinical care. Research laboratory results will not be returned to participants or entered into medical records. The study will describe longitudinal peripheral immune-cell profiles and explore associations among T\u002FB\u002FNK cell phenotypes, T-cell differentiation and senescence\u002Fexhaustion markers, viral imprinting markers, and postoperative residual or new pulmonary nodule evolution.",[25],"Multiple Pulmonary Nodules",[27],"CyTOF","NOT_YET_RECRUITING","2026-06-12",{"date":31,"type":32},"2026-06-15","ACTUAL",{"date":34,"type":20},"2026-07",{"date":36,"type":20},"2028-12",{"name":38,"class":39},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":48,"keywords":49,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":54,"locationsCount":4},"100642174","single-center-cytof-and-viral-imprinting-study-in-postoperative-multiple-pulmonary-nodules-100642174","NCT07647055","Single-Center CyTOF and Viral Imprinting Study in Postoperative Multiple Pulmonary Nodules","A Single-Center Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\n* Age 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\n* Investigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.",{"count":19,"type":20},[25],[27],"2026-06-09",{"date":31,"type":32},{"date":34,"type":20},{"date":36,"type":20},{"name":38,"class":39},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100623340","hybrid-robot-assisted-percutaneous-ablation-and-non-intubated-vats-for-multiple-pulmonary-nodules-100623340","NCT07395362","Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules","A Prospective Single-Arm Study Evaluating the Safety, Feasibility, and Perioperative Recovery of Robot-Assisted Percutaneous Ablation\u002FLocalization Combined With Non-Intubated Video-Assisted Thoracoscopic Surgery for Multiple Pulmonary Nodules","Inclusion Criteria:\n\n1. Age 18 to 85 years at the time of enrollment.\n2. Presence of multiple pulmonary nodules identified on chest computed tomography (CT).\n3. At least one dominant pulmonary lesion meeting standard indications for thoracoscopic surgical resection based on radiologic assessment.\n4. At least one additional pulmonary nodule for which complete surgical resection is considered undesirable due to lung parenchyma preservation concerns or procedural risk, and deemed suitable for robot-assisted CT-guided percutaneous intervention.\n5. Determined by a multidisciplinary team (MDT) to be an appropriate candidate for the predefined hybrid treatment strategy.\n6. Eligible for non-intubated video-assisted thoracoscopic surgery based on preoperative anesthetic evaluation (ASA physical status I-III).\n7. Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Pulmonary nodules located centrally or adjacent to major airways, major vessels, or the heart, where safe percutaneous intervention is not feasible.\n2. Pure ground-glass nodules with a maximum diameter \\\u003C 6 mm, for which active surveillance is recommended.\n3. Clinical evidence of N1\u002FN2 lymph node involvement or distant metastasis.\n4. Severe cardiopulmonary disease, interstitial lung disease, or other conditions that preclude thoracoscopic surgery or anesthesia.\n5. Coagulation disorders or ongoing anticoagulation therapy that cannot be safely discontinued.\n6. Pregnancy or breastfeeding.\n7. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study assessments.","85 Years",{"count":64,"type":20},30,"INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to evaluate the safety and feasibility of a predefined hybrid treatment strategy in patients with multiple pulmonary nodules who require surgical management of at least one dominant lesion. The strategy combines robot-assisted CT-guided percutaneous ablation and\u002For localization with non-intubated video-assisted thoracoscopic surgery (NiVATS) performed during the same hospitalization.\n\nThe main questions this study aims to answer are:\n\nIs the hybrid treatment strategy associated with an acceptable rate of perioperative serious complications?\n\nCan the planned combination of robot-assisted percutaneous intervention and NiVATS be completed successfully in a real-world clinical setting?\n\nParticipants will:\n\nUndergo preoperative evaluation and multidisciplinary assessment;\n\nReceive robot-assisted CT-guided percutaneous ablation and\u002For localization for selected pulmonary nodules;\n\nUndergo non-intubated video-assisted thoracoscopic surgery for resection of the dominant pulmonary lesion;\n\nBe followed for perioperative outcomes and short-term recovery up to 30 days after surgery.",[25],[71,72,73,74,75],"Multiple pulmonary nodules","Ground-glass nodules","Robot-assisted percutaneous ablation","CT-guided intervention","Non-intubated video-assisted thoracoscopic surgery NiVATS","2026-02-06",{"date":78,"type":32},"2026-02-09",{"date":80,"type":20},"2026-02-28",{"date":82,"type":20},"2026-10-01",{"name":38,"class":39},1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":22,"phases":4,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":84},"100551329","a-prospective-non-interventional-cohort-study-of-subsolid-pulmonary-nodules-100551329","NCT06458673","A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules","Prediction of Growth Trend of Pulmonary Nodules Based on Multi-temporal and Multimodal Medical Data and Its Impact on Pulmonary Nodule Management Strategies","Inclusion Criteria:\n\n* Age≥ 18 years old, gender is not limited\n* Confirmed subsolid pulmonary nodule by CT, initial pulmonary nodule ≥ 5 mm (including subsolid components) and ≤ 30 mm, do not shrink or disappear after 3 months Follow-up.\n* ECOG 0～2\n* Able to provide CT in DICOM format\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Long-term use of immunosuppressants and hormone drugs\n* History of previous malignancy (if there is no recurrence or carcinoma in situ for more than 5 years after receiving curative therapy, it can be enrolled)\n* Inability to cooperate with regular follow-up\n* Poor general condition, with the life expectancy less than 6 months",{"count":93,"type":20},1184,"5 Years","Some studies have shown that the model for judging and predicting the growth of sub-solid pulmonary nodules through big data and deep learning can detect nodule growth earlier. Since most of the training data come from large foreign samples, most of the validated data are CT data from a single center or a few centers, and their generalization ability needs to be further verified. In order to better study subsolid pulmonary nodules in the lungs in China, we plan to conduct a prospective, multicenter, non-interventional observational cohort study.",[97,25],"Solitary Lung Nodule",[99,100,101],"Lung Nodule","Prospective","Observational Study","2024-11-27",{"date":104,"type":32},"2024-12-02",{"date":106,"type":20},"2024-12-01",{"date":108,"type":20},"2030-11-30",{"name":110,"class":39},"Guangdong Provincial People's Hospital"]